The basic track will cover the latest updates on mechanisms and treatment targets for different liver diseases.There will be a special focus on hepatic sexual dimorphism, liver autophagy, mRNA splicing in liver disease and the role of bile acids in the brain.

What is new this year?

What does it take to submit a basic science manuscript to the Journal of Hepatology and JHEP Reports? Don’t miss the special interactive session during which you will have the chance to meet up with the scientific editors.

Why should you attend ILC 2022?

Do you have trouble deciding which preclinical model to use for your NASH studies? At this year’s ILC, we will hold a roundtable discussion and try to reach a consensus on the best-preclinical models for NASH.

This track will provide you with an exhaustive overview on the management of patients with decompensated cirrhosis and vascular liver disorders.

What is new this year?

Recent advances on challenging situations such as, varices management, hepatic encephalopathy and splanchnic vein thrombosis will be presented. We will also be discussing the novelties in portal hypertension management agreed on in the recent Baveno VII consensus.

Why should you attend ILC 2022?

This track is a must to all health professionals dedicated to the management of patients with advanced chronic liver disease. The program covers the recent advances of the field and discussion around common clinical dilemmas.

The General Hepatology topic track will be discussing the future of clinical hepatology and providing you with the latest updates in the management, treatment, and diagnosis of liver disease.

What is new this year?

For the first time, there will be an “International Roundtable” session, where the differences in the management of a specific liver complication across different continents will be highlighted.

Why should you attend ILC 2022?

The ILC 2022 is the perfect opportunity to discuss difficult and challenging clinical cases and to hear about the recent advances made in fields such as liver transplantation.

This track will bring you the newest pathophysiologic insights, diagnostic and therapeutic approaches in immune-mediated and cholestatic diseases.

What is new this year?

An overview on novel developments in the diagnosis and treatment of autoimmune hepatitis will be provided and the new EASL Clinical Practice Guidelines for primary and secondary sclerosing cholangitis will be introduced.

Why should you attend ILC 2022?

Don’t miss the ILC 2022 if you want to attend and be a part of the discussions and debates crucial for the identification of new therapeutic targets for autoimmune and cholestatic diseases.

Get up-dated on the physiopathology, diagnosis and treatment of hepatocellular carcinoma and cholangiocarcinoma.

What is new this year?

Discover the new data on the daily care of patients with NASH-related HCC, on managing systemic treatments for primary liver cancer, and the role of tumour heterogeneity in clinical practice.

Why should you attend ILC 2022?

ILC 2022 is a unique opportunity for face-to-face meetings with worldwide experts in the field of liver tumours. And a great occasion to net work with other specialists to foster new collaborations.

This topic track will give you an overview of lifestyle & the liver, an update on the management of sever alcoholic hepatitis and an insight into the therapeutic advancements in NAFLD.

What is new this year?

From genetics to basic studies, we will be giving you novel insights into fatty liver disease pathogenesis and emerging therapeutic targets.

Why should you attend ILC 2022?

Don’t miss this track if you’re interested in updates on therapeutic management of patients with fatty liver disease, the role of lifestyle changes & multidisciplinary care for patients with metabolic dysfunction and the latest results from NAFLD trials.

The Public Health sessions will address the burden of liver disease on a European landscape of risk factors. A particular focus will be placed on alcohol and metabolic liver diseases and the urgent need for screening and prevention.

What is new this year?

For the first time the main actors on the International and European scenes, namely the WHO and the CDC, will come together to discuss the innovation driving viral hepatitis C and B elimination worldwide.

Why should you attend ILC 2022?

At the ILC 2022, experts will explore barriers to liver health improvement and discuss solutions highlighted in the final EASL-Lancet commission report.

With a broad range of clinical courses and outcomes, viral hepatitis remains a major global health burden and the road to eliminate viral hepatitis as an important cause of morbidity and mortality worldwide is full of obstacles.

What is new this year?

We will be discussing how the treatment landscape of HBV and HDV have changed and what the immediate future brings. Also, we will discuss about prevention/treatment through vaccination – what vaccines do we have, which ones are in the pipeline?

Why should you attend ILC 2022?

At ILC 2022, the challenges faced on the road to viral hepatitis elimination will be addressed and cover the spectrum from prevention, over diagnosis and treatment to the management after cure.